Investor Series: Opportunities in the Cell and Gene Therapy Market (Focus on Need for Cell and Gene Therapies, Landscape of Key Innovators, Analysis of Product Offerings and Affiliated Value Propositions, Insights from Historical Funding Activity, Startup Health Indexing and Company Valuation Analysis, Financial Analysis of Key Public Ventures, Market Forecast and Opportunity Analysis, Insights from Publicly Disclosed Investor Exits and Key Acquisition Targets)

  • Lowest Price Guaranteed From USD 1,899

  • Published
    April 2022

  • Slides
    121

  • View Count
    1677

Example Insights

Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Context-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Contemporary-Sentiments-&-Expert-Opinions-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Prominent-Treatment-Variants-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-A-Success-Story-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Key-Innovators-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Company-Health-Indexing-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Analysis-of-Value-Proposition-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Company-Competitiveness-Analysis-thumb
Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Analysis-of-Investments-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Financing-Summary-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Funding-and-Investment-Activity-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Company-Valuation-Analysis-thumb 	Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Financial-Overview-of-Company-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Annual-Revenues-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Analysis-of-Financial-Ratios-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Technical-Financial-Analysis-thumb
Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Company-Stock-Performance-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Key-Indicators-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Business-Risk-Assessment-thumb 	Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Opportunity-Analysis-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Analysis-of-Investor-Exists-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Key-Acquisition-Targets-thumb Investor-Series-Opportunities-in-the-Cell-&-Gene-Therapy-Market-Overview-of-Shortlisted-Dataset-thumb  

Overview

Contemporary medical science has traced thousands of clinical conditions to a genetic cause. Cancer, a life-threatening disease, also has genetic origins, and is considered among the leading causes of death across the globe. In fact, the World Health Organization (WHO) has reported that close to 10 million cancer related deaths annually, across the world. Moreover, experts believe that there are over 7,000 different types of rare diseases (including some rare forms of cancer), most of which originate as a consequence of genetic anomalies. The majority of the aforementioned conditions are still considered incurable. As a result, these disease areas are characterized by a significant unmet need for curative interventions; and therefore, considered among the most lucrative opportunity areas for biopharmaceutical developers. For example, ZOLGENSMA®, a blockbuster product developed by Novartis, and indicated for the treatment of spinal muscular atrophy, generated net revenues of approximately USD 1.35 billion in 2021 alone. The first gene therapy trial was conducted in 1990, and it took almost three decades for the first of such interventions to enter the market. Given recent developments in genetic manipulation, cell biology and molecular targeting, a number of highly specific interventions have been developed against prominent types of cancers and certain rare genetic conditions. Currently, there are over 20 cell and gene therapies approved for use in the United States alone. 

During the COVID-19 pandemic, the pace of R&D in this field slowed down - a consequence of complex manufacturing protocols, extensive logistical considerations and supply chain-related concerns. However, the field still witnessed a considerable inflow of capital, with over USD 21 billion invested into various companies since the start of the pandemic. With over 1,200 product candidates in various stages of development, experts suggest that, by 2025, the US FDA may start approving around 10 to 20 cell and gene therapy products, on an annual basis. It is likely that, over the next two decades, gene therapies facilitate the evolution of medical practice from a treatment-based paradigm to a prevention-focused approach. Despite the fact that niche startups are spearheading the innovation in this domain, several big pharma players are also actively acquiring capabilities related to upcoming advanced therapy medical products (ATMPs). Prominent players in the field, such as Juno Therapeutics, AveXis, and Kite Pharma, have been acquired as a consequence of the rapid expertise building efforts of more established pharma companies. Moreover, gene therapy-focused businesses that have gone public, have experienced considerable growth in share value as their respective products / product candidate progressed through the various stages of development. Taking into consideration both the historical and contemporary scenario, the cell and gene therapies market continues to present lucrative investment opportunities for both short- and long-term investors.

Scope of the Report

The “Investor Series: Opportunities in the Cell and Gene Therapy Market” report provides detailed information on the cell and gene therapy industry, covering both core and peripheral products, and affiliated services. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data. The report features the following details:

  • A qualitative and quantitative (wherever information was available) perspective on the current need for cell and gene therapies. It also provides information on some of the important applications of cell and gene therapies, the benefits of using such therapies over conventional treatment options, the various challenges faced in the development / production of these ATMPs, and the opinions of  representatives from key stakeholder companies involved in this domain. It also includes details of some exemplary ventures that have either succeeded or failed in this market, and highlights the various events, related to this field of research, which have already taken place, or yet to take place, since 2020. 
  • A detailed analysis of cell and gene therapy focused companies that were established on or after 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, headquarters, company size, and type of venture. 
  • A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, which was informed via secondary research. 
  • An assessment of the various products and affiliated services, offered by the companies mentioned above, featuring analysis based on number and type of product, and an informed perspective on the value of the aforementioned offerings based on multiple relevant aspects, namely, therapy-related value, value to patients, developer value, and others.  
  • A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in the development of cell and gene therapies / product candidates, captured in this report. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analyses.
  • A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. Further, it features a list of the leading investors in cell and gene therapy market, based on their participation in financing activity in this industry segment. 
  • A proprietary analysis defining a basis for estimating the relative valuation of the private companies among the key innovators discussed in this report. The value statements generated under this analytical framework, were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were then extrapolated using the appropriate mathematical models to generate the likely valuation estimates for all the companies in the dataset.
  • An elaborate review of the overall cell and gene therapy market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the key innovators dataset. 
  • A business risk analysis, focused on some of the major categories of risk that are usually discussed in the industry – namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks. 
  • Case studies of instances where investors have exited various cell and gene therapy-related ventures, offering insights on returns on investment made (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the cell and gene therapy market. 
  • A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of cell and gene therapies over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035. The opportunity has been segregated on the basis of [A] key market segments (namely stem cell therapies, gene therapies and T-cell therapies) [B] therapeutic areas (namely oncological disorders, genetic disorders, metabolic disorders and others) [C] routes of administration (intravenous and others) and [D] geography (North America, Europe, Asia Pacific and the rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Contents

Chapter Outlines

EXCEL DELIVERABLE

Spreadsheet I includes details on the key innovator companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, inputs for a detailed company competitiveness analysis and a shortlist of industry stakeholders that were deemed to be likely targets of mergers / acquisitions, in the near future. The deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated within. 

Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in cell and gene therapies (since 2011). 

Spreadsheet III showcases our proprietary company valuation analysis, wherein we have developed the means to extrapolate publicly information (related to valuation of specific companies) to develop informed estimates of the likely value of a company. 

Spreadsheet IV is a collection of multiple MS Excel sheets that provide summaries of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the key innovators dataset. 

Spreadsheet V offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well. 

Spreadsheet VI is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with cell and gene therapies.  

Spreadsheet VII includes publicly available information on the investments made by select investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on likely returns on investment received by the mentioned investors. 

POWERPOINT DELIVERABLE

Chapter 1 provides a brief summary of the content presented in the report, beginning with the need for cell and gene therapies. It goes on to discuss some of the key benefits of these medical products and their advantages over other available drugs / therapies. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years. 

Chapter 2 and 3 feature brief (pictorial) summaries of the key objectives and approach used for data collection and analysis, in this study. 

Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report. 

Section I: Need for Cell and Gene Therapies & Key Innovators Landscape
Chapter 5 describes the current need for cell and gene therapies, and highlights key facts about the origin and development of such ATMPs. It features information on current areas of innovation, along with the opinions of experts, describing the various benefits of these therapies, and anticipated future challenges. It includes information on some of the key players that are engaged in this domain, along with examples of ventures that have either succeeded or failed in the market. The views presented in this chapter are backed by inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts). It concludes with information on the different conferences that have been conducted in this domain in the recent past, and those that are planned for the near future. 

Chapter 6 focuses on some of the key innovators (companies established on or after 2005) and features detailed analysis of the aforementioned companies. It highlights important company related details, such as year of establishment, headquarters, company size, and type of venture. 

Chapter 7 includes information on the various products and affiliated services offered by the companies captured in the report (listed in Chapter 6). It also features analysis based on number and type of product. Based on the aforementioned insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies. 

Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely, treatment-related value offered, value to patients and technology related value, we developed an empirical framework to quantify the value proposition of a business. 

Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developed of diverse cell and gene therapies captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criteria, which was informed via our company health indexing and valuation exercise. 

Section II Analysis of Investments & Company Valuation 
Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. 

Chapter 11 features a proprietary basis for estimating the relative valuation of private companies, among the key innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.

Section III Financial Analysis & Assessment of Business Risks
Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall cell and gene therapy market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of six of the publicly listed companies within the key innovators dataset. 

Chapter 13 includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.

Section IV Market Forecast & Opportunity Analysis
Chapter 14 features is an insightful market forecast analysis, highlighting the estimated current and future sizes of overall cell and gene therapy market till the year 2035. The opportunity has been segregated on the basis of [A] key market segments (namely stem cell therapies, gene therapies and T-cell therapies) ) [B] therapeutic areas (namely oncological disorders, genetic disorders, metabolic disorders and others) [C] routes of administration (intravenous and others) and [D] geography (North America, Europe, Asia Pacific and the rest of the world) . 

Section V Analysis of Returns on Investment & Key Acquisition Targets
Chapter 15 includes case studies of instances where investors have exited various cell and gene therapy-related ventures, offering insights on returns on investment made (based on availability of data). The abovementioned estimates / details, offer a perspective on how past investments have paid off for investors as companies gradually went public, over time. 

Chapter 16 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets. 

Chapter 17 provides a pictorial summary of the overall project.

Chapter 18 is a set of appendices.

Table Of Contents

Excel Deliverable
1. Key Innovators & Products Dataset
1.1. Analysis Notes
1.2. Summary Dashboard
1.3. Innovators Landscape Dataset
1.4. Product Landscape Dataset
1.5. Company Health Indexing
1.6. Value Proposition Analysis
1.7. Key Acquisition Targets
A1 – A8 Appendices

2. Funding & Investments Analysis
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in cell and gene therapy
A1 – A2 Appendices

3. Company Valuation Analysis
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
A1 – A2 Appendices

4. Fundamental & Technical Financial Analysis
The information presented in this analysis is spread across separate MS Excel sheets, which provide information on key financial parameters and competitive insights based on historical and prevalent trends. 

5. Business Risk Analysis
5.1. Analysis Notes
5.2. Business Risk Data
A1 – A2 Appendices

6. Market Forecast & Opportunity Analysis
6.1. Analysis Notes
6.2. Summary Dashboard
6.3. Market Forecast & Opportunity Analysis
A1 – A2 Appendices

7. Returns on Investment
7.1. Analysis Notes
7.2. Estimated RoI for Investors in Company A
7.3. Estimated RoI for Investors in Company B
7.4. Estimated RoI for Investors in Company C
7.5. Estimated RoI for Investors in Company D
7.6. Estimated RoI for Investors in Company E
7.7. Estimated RoI for Investors in Company F
7.8. Estimated RoI for Investors in Company G
7.9. Estimated RoI for Investors in Company H
7.10. Estimated RoI for Investors in Company I
7.11. Estimated RoI for Investors in Company J
A1 – A2 Appendices

PowerPoint Deliverable 
1. Context

2. Project Approach

3. Project Objectives

4. Executive Summary

Section I: Need for Cell and Gene Therapy & Key Innovators Landscape 
5. The Cell and Gene Therapy Market
5.1. Overview
5.2. Contemporary Sentiments & Expert Opinions
5.3. Key Areas of Application
5.4. Benefits of Cell and Gene Therapies
5.5 Developmental History
5.6 Exemplary Products
5.7. Challenges related to Cell and Gene Therapies
5.7 Key Initiatives in the Cell and Gene Therapy Market (Case Studies)
5.8.1. Exemplary Business Successes
5.8.2. Exemplary Business Failures
5.9. Analysis of Recent Conferences

6. Key Innovators Competitive Landscape
6.1. Key Innovators in the Cell and Gene Therapy Market
6.2. Analysis of Developer Landscape

7. Products Landscape & Company Health Indexing
7.1. List of Products
7.2. Analysis of Product Landscape
7.3. Health Indexing Methodology
7.4. Company Health Indexing
7.3. Concluding Remarks

8. Value Proposition Analysis
8.1. Overview & Methodology
8.2. Therapy Related Value
8.3. Value to Patients
8.4. Technology Related Value
8.5. Developer Value

9. Company Competitiveness Analysis
9.1. Overview & Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks

Section II Analysis of Investments & Company Valuation 
10. Funding and Investments Analysis
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography
10.4. Most Active Companies and Popular Investors
10.5. Analysis of Trends Associated with Individual Funding Categories
10.6. Funding and Investments Summary

11. Company Valuation Analysis
11.1. Overview & Methodology
11.2. Results of Valuation Analysis

Section III Financial Analysis & Assessment of Business Risks 
12. Financial Analysis of Public Ventures
12.1. Overview
12.2. Company A
12.2.1. Fundamental Analysis of Company Financials
12.2.1.1. Insights from Balance Sheet
12.2.1.2. Analysis of Financial Ratios
12.2.2. Technical Analysis of Stock Price
12.2.2.1. Historical Trends
12.2.2.1. Recent Trends

12.3. Company B
12.3.1. Fundamental Analysis of Company Financials
12.3.1.1. Insights from Balance Sheet
12.3.1.2. Analysis of Financial Ratios
12.3.2. Technical Analysis of Stock Price
12.3.2.1. Historical Trends
12.3.2.1. Recent Trends

12.4. Company C
12.4.1. Fundamental Analysis of Company Financials
12.4.1.1. Insights from Balance Sheet
12.4.1.2 Analysis of Financial Ratios
12.4.2. Technical Analysis of Stock Price
12.4.2.1. Historical Trends
12.4.2.1. Recent Trends

12.5. Company D
12.5.1. Fundamental Analysis of Company Financials
12.5.1.1. Insights from Balance Sheet
12.5.1.2. Analysis of Financial Ratios
12.5.2. Technical Analysis of Stock Price
12.5.2.1. Historical Trends
12.5.2.1. Recent Trends

12.6. Company E
12.6.1. Fundamental Analysis of Company Financials
12.6.1.1. Insights from Balance Sheet
12.6.1.2 Analysis of Financial Ratios
12.6.2. Technical Analysis of Stock Price
12.6.2.1. Historical Trends
12.6.2.1. Recent Trends

12.7. Company F
12.7.1. Fundamental Analysis of Company Financials
12.7.1.1. Insights from Balance Sheet
12.7.1.2 Analysis of Financial Ratios
12.7.2. Technical Analysis of Stock Price
12.7.2.1. Historical Trends
12.7.2.1. Recent Trends

12.8. Company G
12.8.1. Fundamental Analysis of Company Financials
12.8.1.1. Insights from Balance Sheet
12.8.1.2 Analysis of Financial Ratios
12.8.2. Technical Analysis of Stock Price
12.8.2.1. Historical Trends
12.8.2.1. Recent Trends

12.9. Company H
12.9.1. Fundamental Analysis of Company Financials
12.9.1.1. Insights from Balance Sheet
12.9.1.2 Analysis of Financial Ratios
12.9.2. Technical Analysis of Stock Price
12.9.2.1. Historical Trends
12.9.2.1. Recent Trends

12.10. Company I
12.10.1. Fundamental Analysis of Company Financials
12.10.1.1. Insights from Balance Sheet
12.10.1.2 Analysis of Financial Ratios
12.10.2. Technical Analysis of Stock Price
12.10.2.1. Historical Trends
12.10.2.1. Recent Trends

12.11. Company J
12.11.1. Fundamental Analysis of Company Financials
12.11.1.1. Insights from Balance Sheet
12.11.1.2 Analysis of Financial Ratios
12.11.2. Technical Analysis of Stock Price
12.11.2.1. Historical Trends
12.11.2.1. Recent Trends

13. Business Risk Analysis
13.1. Overview and Methodology
13.2. Operations-related Risks
13.3. Business-related Risks
13.4. Financial / Asset-related Risks
13.5. Product / Technology Risks
13.6. Other Risks
13.8. Business Risk Summary

Section IV Market Forecast & Opportunity Analysis 
14. Market Forecast and Opportunity Analysis
14.1. Overview and Methodology
14.2. Overall Cell and Gene Therapy Market Size, 2021-2035
14.2.1. Analysis by Key Market Segments
14.2.2. Analysis by Geography
14.2.3. Concluding Remarks

Section V Analysis of Returns on Investment & Key Acquisition Targets 
15. Analysis of Returns on Investment
15.1. Overview & Methodology
15.2. Case Studies
15.3. Concluding Remarks

16. Key Acquisition Targets
16.1. Overview
16.2. List of Key Acquisition Targets
16.3. Concluding Remarks

17. Conclusion

18. Appendices

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 4BIO Capital
  2. 4D Molecular Therapeutics
  3. 5AM Venture
  4. 600 Mile Challenge Fund
  5. AavantiBio
  6. aaVective    
  7. AAVogen
  8. Abata Therapeutics
  9. AbbVie Ventures
  10. Abby Grace Foundation
  11. AbCheck
  12. AbClon
  13. Abdi Ibrahim
  14. Abeona Therapeutics
  15. Abingworth
  16. Abintus Bio
  17. Access Biotechnology
  18. Adage Capital Management
  19. Adaptate Biotherapeutics
  20. Adaptimmune Therapeutics
  21. Adicet Bio
  22. Adjuvant Capital
  23. Advantagene
  24. Advaxis
  25. Adverum Biotechnologies
  26. Aegle Therapeutics
  27. Aeon Therapeutics
  28. Affinia Therapeutics
  29. AffyImmune Therapeutics
  30. Agent Capital
  31. AgenTus Therapeutics
  32. Agenus
  33. AGTC
  34. AIG
  35. Aisling
  36. Aisling Capital
  37. AJU IB Investment
  38. Akouos
  39. Alexandria Venture Investments
  40. Algot Invest
  41. Aligned Genetics
  42. Allergan    
  43. ALLIFE    
  44. Allogene Therapeutics
  45. AlloVir
  46. Ally Bridge Group
  47. Alpha Holdings
  48. AlphaVax
  49. Altaco XXI
  50. Altheia Science
  51. Altitude Life Science Ventures
  52. Altor Bioscience
  53. Alumni Ventures
  54. Amarna Therapeutics
  55. Ambulero
  56. American Gene Technologies
  57. Amgen
  58. Amgen Ventures
  59. Amicus Therapeutics
  60. Amplo
  61. Anaeropharma Science
  62. AnGes
  63. Angiocrine Bioscience
  64. Angionetics
  65. Anhui Kedgene Biotechnology
  66. Antagene
  67. Anterogen
  68. Anzu Partners
  69. apceth Biopharma
  70. ApolloBio
  71. Apple Tree Partners
  72. ARBELE
  73. Arcane Investment
  74. Arcellx
  75. Arch Overage Fund
  76. ARCH Venture Partners
  77. Arctic Light Venture Capital
  78. Arix Bioscience
  79. Arkin Bio Ventures
  80. ArrowMark Partners
  81. ARTIS Ventures
  82. Aruvant Sciences
  83. ASC Therapeutics
  84. Ascendant BioCapital
  85. Asia Alpha
  86. Asklepios BioPharmaceutical (AskBio)
  87. Aspire Capital Fund
  88. Astellas Pharma
  89. Astellas Venture Management
  90. AstraZeneca
  91. Atara Biotherapeutics
  92. Athersys
  93. Atlas Venture
  94. Atsena Therapeutics
  95. Audentes Therapeutics
  96. Auriga Partners
  97. Aurora Biopharma
  98. Autolus
  99. Avacta
  100. AveXis
  101. Avidity Partners
  102. AVROBIO
  103. Axis Biotec Brasil
  104. Axovant Gene Therapies
  105. Azidus Brasil
  106. Baillie Gifford
  107. Bain Capital Life Sciences
  108. Barer & Son Capital
  109. Bayer Global Investments
  110. Baylx
  111. BB Pureos Bioventures
  112. Beam Therapeutics
  113. Beijing 302 Hospital
  114. Beijing Biohealthcare Biotechnology
  115. Beijing Doing Biomedical
  116. Beijing Immunochina Medical Science & Technology
  117. Bellicum Pharmaceuticals
  118. Berkeley Catalyst Fund
  119. BHI Therapeutic Sciences
  120. BHT Lifescience Australia
  121. BioAtla
  122. BioCardia
  123. Bioceltech Therapeutics
  124. Biogen
  125. BioGenCell
  126. Bioinova
  127. BioInvent International
  128. BioMarin Pharmaceutical
  129. Biomatics
  130. Biomatics Capital
  131. Bionic Sight
  132. BioNTech
  133. Bioquark
  134. BioRestorative Therapies
  135. BioTrack Capital
  136. BioVec Pharma
  137. Bioverativ
  138. Biox Biosciences
  139. Birk Venture
  140. BlackRock
  141. Blackstone Life Sciences
  142. Blue Bear Ventures
  143. Blue Water Angels
  144. bluebird bio
  145. Bluebird Ventures
  146. BlueWater Angels
  147. Boehringer Ingelheim
  148. Boehringer Ingelheim Venture Fund
  149. Bone Therapeutics
  150. Boxer Capital
  151. Boxer Capital of Tavistock Life Sciences
  152. BPI France
  153. Bpifrance
  154. Brace Pharma Capital
  155. Brahman Investment
  156. Brain Neurotherapy Bio
  157. BrainStorm Cell Therapeutics
  158. BrainVectis
  159. Breakout Ventures
  160. BridgeBio
  161. BrightGene
  162. Bristol-Myers Squibb
  163. Brookside Capital
  164. Bukwang Pharmaceutical
  165. BVF Partners
  166. C4 holding
  167. CaaS Capital
  168. Caladrius Biosciences
  169. CAM Capital
  170. Cambridge Enterprise
  171. Cambridge Gene Therapy
  172. Cambridge Innovation Capital
  173. Camford Capital
  174. CapDecisif Management
  175. Capricor Therapeutics
  176. CARB-X
  177. Carina Biotech
  178. Carmine Therapeutics
  179. CARsgen Therapeutics
  180. CAR-T (Shanghai) Biotechnology
  181. CAR-T (Shanghai) Cell Biotechnology
  182. Cartesian Therapeutics
  183. Cartherics
  184. Casdin Capital
  185. Castle Creek Biosciences
  186. Catalyst Biosciences
  187. CavoGene LifeSciences
  188. Celgene Corporation
  189. Celixir
  190. Cell Therapy Catapult
  191. Cellectis
  192. Cellenkos
  193. Cellerant Therapeutics
  194. CellGenTech
  195. CellProthera
  196. Cellular Biomedicine Group
  197. Cellular Therapeutics
  198. Celsion
  199. Celyad Oncology
  200. CENTOGENE
  201. Cesca Therapeutics
  202. CG Oncology
  203. CHABiotch
  204. Chiesi Farmaceutici
  205. Chiesi Ventures
  206. China Immunotech (Beijing) Biotechnology
  207. China Merchant Bank International Capital
  208. Chiyoda-ku
  209. Chongqing Precision Biotech
  210. Chongqing Precision Biotechnology
  211. Clarus Ventures
  212. Clough Capital Partners
  213. CMG-SDIC Capital
  214. CODA Biotherapeutics
  215. Codexis
  216. Columbus Venture Partners
  217. CombiGene
  218. Consort Medical
  219. Copernicus Therapeutics
  220. Corestem
  221. Cormorant Asset Management
  222. Cormorant Capital
  223. Cota Capital
  224. Cowen Group
  225. Co-Win Ventures
  226. Coya Therapeutics
  227. CRISPR Therapeutics
  228. CSL Behring
  229. CureDuchenne Ventures
  230. Cynata Therapeutics
  231. Cynvec
  232. Cystic Fibrosis Foundation Therapeutics
  233. CytoMed Therapeutics
  234. Cytopeutics
  235. Cytovant Sciences
  236. D1 Capital Partners
  237. DA Value Partners
  238. DAG Ventures
  239. Daily Partners
  240. Deerfield Management Company
  241. DEFTA Partners
  242. Dexcel Pharma
  243. DiNAQOR
  244. DiscGenics
  245. DNAlite Therapeutics
  246. DNAtrix
  247. Domain Associates
  248. Driehaus Capital Management
  249. DriveCapital
  250. DS Asset Management
  251. Dyno Therapeutics
  252. EB Medical Research Foundation
  253. EB Research Partnership
  254. EB5 Life Sciences
  255. EcoR1 Capital
  256. Editas Medicine
  257. EHL Bio
  258. Eight Roads Ventures
  259. Elaia Partners
  260. Elevate Bio
  261. Eli Lilly
  262. Emendo Biotherapeutics
  263. Encoded Therapeutics
  264. Endocyte
  265. Endsulin
  266. Enochian BioSciences
  267. Entos Pharmaceuticals
  268. Epeius Biotechnologies
  269. EpiBone
  270. EpiVax
  271. EPS Holdings
  272. Errant Gene Therapeutics
  273. Esco Ventures
  274. Essex Bio-Technology
  275. Esteve
  276. Eureka Therapeutics
  277. eureKARE
  278. Eurofancolen
  279. Eutilex
  280. Eventide Asset Management
  281. Ever Supreme Bio Technology
  282. Evotec
  283. Excision BioTherapeutics
  284. Exegenesis Bio
  285. Expression Therapeutics
  286. ExSight Capital
  287. EXUMA Biotech
  288. Eyevensys
  289. F2 Ventures
  290. Farallon Capital
  291. Fate Therapeutics
  292. FerGene
  293. Ferrer International
  294. Ferring Pharmaceuticals
  295. FF Science
  296. Fibrocell Science
  297. Fidelity Biosciences
  298. Fidelity Management & Research Company
  299. Fin Posillipo
  300. Five Prime Therapeutics
  301. Flagship Pioneering
  302. Flagship Ventures
  303. Flanders Innovation & Entrepreneurship
  304. Flash Therapeutics
  305. Flerie Invest
  306. Flexion Therapeutics
  307. Forbion’s Growth Opportunities Fund
  308. Foresite Capital Management
  309. Forevertek Biotechnology
  310. Forge Biologics
  311. Formula Pharmaceuticals
  312. Fortress Biotech
  313. Fosun Capital
  314. Fosun Pharma
  315. Fountain Healthcare Partners
  316. FoxKiser and Fidelity BioSciences
  317. F-Prime Capital
  318. Franklin Templeton Investments
  319. Frazier Healthcare Partners
  320. Freeline Therapeutics
  321. Friedreich’s Ataxia Research Alliance
  322. FS Development
  323. Fujian Cancer Hospital
  324. Fund+
  325. Fundamenta Therapeutics
  326. Gadeta
  327. Galia Gestion
  328. Gamida Cell
  329. GammaCell Bio-Technologies
  330. GammaDelta Therapeutics
  331. GC Cell
  332. Gemini Therapeutics
  333. Gene Therapy Research Institution
  334. GeneCure Biotechnologies
  335. Genelux
  336. GeneMedicine
  337. Genenta Science
  338. GeneOne Life Science
  339. GeneQuine Biotherapeutics
  340. Generation Bio
  341. Genespire
  342. Genethon
  343. Genexine
  344. Genocea
  345. Genprex
  346. GenSight Biologics
  347. GentiBio
  348. Genus Oncology
  349. GenVec
  350. Genzyme
  351. Georgia Research Alliance
  352. Ghost Tree Capital Group
  353. GigaGen
  354. Gilde Healthcare
  355. Gilead Sciences
  356. GlaxoSmithKline
  357. Global Cell Med
  358. Glycostem Therapeutics
  359. GN Tech Venture
  360. GO CAPITAL
  361. GOFAR
  362. Google Venture
  363. Gracell Biotechnologies
  364. Gradalis
  365. Grand Mount Capital
  366. Gray’s Creek Capital Partners
  367. GreatPoint Ventures
  368. Green Cross Holdings
  369. Guangzhou FineImmune Biotechnology
  370. Guangzhou Institute of Respiratory Disease
  371. Guofang Capital
  372. Gwo xi Stem Cell
  373. Gyroscope Therapeutics
  374. Handl Therapeutics
  375. Harvest Capital
  376. Hatteras Venture Partners
  377. HBM Healthcare Investments
  378. HealthCap
  379. Hebei Newtherapy BIo-Pharma Technology
  380. Hebei Senlang Biotechnology
  381. Helix BioPharma
  382. Helixmith
  383. Hemera Biosciences
  384. Hemostemix
  385. Henan Hualong Biotechnology
  386. Herantis Pharma
  387. Hercules Capital
  388. Hercules Technology Growth Capital
  389. High-Tech Gründerfonds
  390. Hillhouse Capital Group
  391. Hiroshima Venture Capital
  392. Hitachi Chemical
  393. Hoga
  394. Holostem Terapie Avanzate
  395. Homology Medicines
  396. Hongkou
  397. Hope Biosciences
  398. HORAMA
  399. Horizon Discovery
  400. Horizon Technology Finance Corporation
  401. Hovione Scientia
  402. Hrain Biotechnology
  403. HuaDao (Shanghai) Biomedical
  404. Huapont Life Sciences
  405. iCarTAB BioMed
  406. iCell Gene Therapeutics
  407. Icell Kealex Therapeutics
  408. Idinvest
  409. Ikarian Capital
  410. Ikarovec
  411. Illumina Ventures
  412. Ilya Pharma
  413. Immatics
  414. Immetacyte
  415. Immune Therapeutics
  416. Immunocore
  417. Immusoft
  418. Imperial Innovations
  419. Imperial Innovations Group
  420. IN8bio
  421. Inception Capital Management
  422. Index Ventures
  423. IndusAge Partners
  424. InnoAngel
  425. Innobio
  426. Innovate UK
  427. Innovative Cellular Therapeutics
  428. InnoVision Capital
  429. Inovio Pharmaceuticals
  430. Inserm Transfert
  431. Intellia Therapeutics
  432. Intima Bioscience
  433. Invectys
  434. Invesco Perpetual
  435. Investment bank of the state of Brandenburg
  436. Invus
  437. Iovance Biotherapeutics
  438. PolyBioCept
  439. IVERIC bio
  440. Janssen
  441. Janus Capital Management
  442. Japan Tissue Engineering
  443. jCyte
  444. JDRF T1D Fund
  445. Jennison Associates
  446. JINWEI
  447. Johnson & Johnson Development
  448. JSC Lancaster Group
  449. Juda Capital
  450. JumpStart
  451. Juno Therapeutics
  452. Juventas Cell Therapy
  453. JW Biotechnology
  454. JW Therapeutics
  455. K2 Venture Partners
  456. Kadimastem
  457. KAEDI
  458. Kangstem Biotech
  459. Kecellitics Biotech
  460. Key Biologics
  461. Kissei Pharmaceutical
  462. Kite Pharma
  463. KKR
  464. Kleiner Perkins Caufield & Byers
  465. KLSMC Stem Cells
  466. Kodikaz Therapeutic Solutions
  467. Kolon Investment
  468. Kolon TissueGene
  469. Korea Investment Partners
  470. Kriya Therapeutics
  471. Krystal Biotech
  472. KSQ Therapeutics
  473. K-Stem Cell
  474. Kubota Vision
  475. Kurma Partners
  476. Kuur Therapeutics
  477. Kyorin Pharmaceutical
  478. Kyverna Therapeutics
  479. Lacerta Therapeutics
  480. Lai Corporation
  481. Lake Bleu Capital
  482. Laurion Capital Management
  483. Lava Therapeutics
  484. Leerink Partners
  485. Leeyeon Investment Association
  486. Leeyon Pharmaceutical
  487. Legend Biotech
  488. Legend Capital
  489. Lentistem® Biotech
  490. Leucid Bio
  491. LEXEO Therapeutics
  492. Life Sciences Partners
  493. LifeArc
  494. Lightstone Ventures
  495. Lilly Asia Ventures
  496. Limelight Bio
  497. Liminatus Pharma
  498. Lineage Cell Therapeutics
  499. Linked Vision
  500. Lion TCR
  501. Living Pharma
  502. LogicBio Therapeutics
  503. Logos Capital
  504. Lokon Pharma
  505. Longeveron
  506. Longitude Capital
  507. Longwood Fund
  508. Loreda Holdings
  509. Lumira Ventures
  510. Lundbeckfond Ventures
  511. Lupus Ventures
  512. LYFE Capital
  513. Lysogene
  514. Lytix Biopharma
  515. MabVax Therapeutics Holdings
  516. Magellan Biologicals
  517. Magenta Therapeutics
  518. Malin Corporation
  519. Mangrove Partners
  520. Marshall Wace
  521. Matrix Capital Management
  522. Maverick Ventures
  523. MaxCyte
  524. Med Cell Bahamas
  525. Medeor Therapeutics
  526. Medigene
  527. MEDIPOST
  528. Medisix Therapeutics
  529. Medison Ventures
  530. MeiraGTx
  531. Melbourne Stem Cell Centre
  532. Mercia Technologies
  533. Merck
  534. Meridigen Biotech
  535. Mesa Verde Venture Partners
  536. Mesoblast
  537. Michigan Economic Development
  538. MidCap Financial
  539. Midven’s Rainbow Seed Fund
  540. Mie University
  541. Milo Biotechnology
  542. Miltenyi Biomedicine
  543. Miltenyi Biotec
  544. Minerva Biotechnologies
  545. MingJu Therapeutics
  546. Minovia Therapeutics
  547. MiraeAsset Financial Group
  548. Mitsubishi Tanabe Pharma
  549. MolMed
  550. Momotaro-Gene
  551. Morningside
  552. MPM Capital
  553. MRL Ventures Fund
  554. MultiVir
  555. Muscular Dystrophy Association
  556. Mustang Bio
  557. Myosana Therapeutics
  558. Nanjing Bioheng Biotech
  559. NanoCor Therapeutics
  560. Narya Capital
  561. National Holdings
  562. Nature Cell
  563. Navega Therapeutics
  564. Nektar Therapeutics
  565. NeoMed
  566. Nerveda
  567. Netherlands Enterprise Agency
  568. NeuExcell Therapeutics
  569. Neuracle Genetics
  570. Neurogene
  571. NeuroGeneration
  572. Neurophth Therapeutics
  573. New Enterprise Associates
  574. New Leaf Venture Partners
  575. NexImmune
  576. NextCell Pharma
  577. Ninevah Therapeutics
  578. Nippon Regenerative Medicine
  579. Nipro
  580. Nissei Capital No. 9
  581. Nitosei Capital
  582. Noga Therapeutics
  583. Nohla Therapeutics
  584. Noile-Immune Biotech
  585. Nolan Capital
  586. Noray Biosciences Group
  587. Northern Light Venture Capital
  588. Northpond Ventures
  589. Norwegian Research Council
  590. Norwest Venture Partners
  591. Noshaq
  592. Nova Immunotherapeutics
  593. Novadip Biosciences
  594. Novartis
  595. Novartis Pharmaceuticals
  596. Novartis Venture Fund
  597. Novo Holdings
  598. Novo Nordisk
  599. Novo Ventures
  600. NuVasive
  601. Oaktree Capital Management
  602. Obsidian Therapeutics
  603. Octagon Capital
  604. Ocugen
  605. Odylia Therapeutics
  606. Olive Tree Capital
  607. Omega Funds
  608. Omnes Capital
  609. Omnimed Capital
  610. Oncolys BioPharma
  611. Onconetics Pharmaceuticals
  612. OncoSec Immunotherapies
  613. oNKo-innate
  614. Ono Pharmaceutical
  615. Optipharm
  616. OrbiMed
  617. Orca Bio
  618. ORCA Therapeutics
  619. Orchard Therapeutics
  620. ORI Capital
  621. ORI Healthcare Fund
  622. Oriza Holdings
  623. Orphinic Scientific
  624. Orthofix
  625. OS Therapies
  626. Osage University Partners
  627. Osiris Therapeutics
  628. Otonomy
  629. ovio Pharmaceuticals
  630. Oxford BioMedica
  631. Oxford Finance
  632. Oxular
  633. Pacira BioSciences
  634. PACT Pharma
  635. Pappas Capital
  636. Paragon Biosciences
  637. Parent Project Muscular Dystrophy
  638. Parkwalk
  639. Partners Innovation Fund
  640. Partners Investment
  641. Passage Bio
  642. Patient Square Capital
  643. Pattern BioScience
  644. Pavilion Capital
  645. PBM Capital
  646. PeproMene Bio
  647. Perceptive Advisors
  648. Perceptive Xontogeny Venture Fund
  649. PeriphaGen
  650. Perseverance Capital Management
  651. Personalized Stem Cells
  652. PersonGen BioTherapeutics (Suzhou)
  653. Pfizer
  654. Pfizer Venture Investments
  655. Pfizer Ventures
  656. Pharmicell
  657. Phio Pharmaceuticals
  658. Phoenix Nest
  659. PhorMed
  660. Piedmont Capital Partners
  661. Pinze Lifetechnology
  662. Pivotal bioVenture Partners
  663. Pluristem Therapeutics
  664. Plus Therapeutics
  665. Polaris Partners
  666. PolyBioCept
  667. Pontifax Venture Capital
  668. POSCO Capital
  669. Poseida Therapeutics
  670. Precigen
  671. Precision BioSciences
  672. Prevail Therapeutics
  673. Progenics Pharmaceuticals
  674. ProMab Biotechnologies
  675. Promethera Biosciences
  676. Protheragen
  677. PsiOxus Therapeutics
  678. PTC Therapeutics
  679. Q Therapeutics
  680. Quad Asset Management
  681. Quell Therapeutics
  682. QVT
  683. RA Capital Management
  684. RBV Capital
  685. Redbiotec
  686. Redmile Group
  687. Redpin Therapeutics
  688. Regeneron Pharmaceuticals
  689. Regeneus
  690. Regenexx
  691. REGENXBIO
  692. Reliance Life Sciences
  693. ReNeuron
  694. Renova Therapeutics
  695. resTORbio
  696. Rev1 Ventures
  697. Reyon Pharmaceutical
  698. Ridgeback Capital Management
  699. Ring Therapeutics
  700. Riordan Technologies
  701. RO Invest
  702. Roche
  703. Roche Venture Fund
  704. Rock Springs Capital Management
  705. Rocket Pharmaceuticals
  706. ROHTO Pharmaceutical
  707. Rottapharm Biotech group
  708. RTI Surgical
  709. RTW Investments
  710. RVO
  711. Sabby Capital
  712. Saehan Startup Investment
  713. Salvat
  714. Samsara BioCapital
  715. Samum Vermögensverwaltungs
  716. SanBio
  717. Sanford Health
  718. Sangamo Therapeutics
  719. Sanofi
  720. Sanofi Ventures
  721. Santen Pharmaceutical
  722. Sarepta Therapeutics
  723. SBI Japan-Israel Innovation Fund
  724. Scancell
  725. Sclnow Biotechnology 
  726. SCM Lifescience
  727. Scotia Biologics
  728. SDL Ventures
  729. Seattle Genetics
  730. Selecta Biosciences
  731. Seneca Biopharma
  732. Sensei Biotherapeutics
  733. Sentien Biotechnologies
  734. Sequoia Capital China
  735. Seroba Life Sciences
  736. Servier
  737. Seven Tree Equity Partners
  738. Sham Innovation Santé
  739. Shandong Qilu Stem Cells Engineering
  740. Shanghai Biomed-Union Biotechnology
  741. Shanghai Bioray Laboratory
  742. Shanghai GeneChem
  743. Shanghai iCELL Biotechnology
  744. Shanghai Longyao Biotechnology
  745. Shanghai PerHum Therapeutics
  746. Shanghai Sunway Biotech
  747. Shanghai Unicar-Therapy Bio-medicine Technology
  748. Shenzhen Binde Biotechnology
  749. Shenzhen BinDeBio
  750. Shenzhen Hornetcorn Biotechnology
  751. Shenzhen Qianhai Taxus
  752. Shire
  753. Sibiono GeneTech
  754. SIGHT AGAIN project
  755. Silicon Valley Bank
  756. SillaJen
  757. Sinobioway Cell Therapy
  758. Skolkovo Foundation
  759. SMBC venture
  760. SNU Bio Angel
  761. Sofinnova Ventures
  762. Sofinnova Investments
  763. Solid Biosciences
  764. Song Hong Fang
  765. Sonoma Biotherapeutics
  766. Sorrento Therapeutics
  767. SOSV
  768. Spark Therapeutics
  769. Sphera Global Healthcare
  770. Spirovant Sciences
  771. SpringWorks Therapeutics
  772. SROne
  773. Stem Cell Medicine
  774. Stem Med
  775. Stemedica Cell Technologies
  776. Steminent Biotherapeutics
  777. Stempeutics Research
  778. StrideBio
  779. Stryker
  780. Sumitomo Dainippon Pharma
  781. Sun Pharmaceutical Industries
  782. Sunshine Insurance
  783. Surveyor Capital
  784. Suvretta Capital Management
  785. SV Health Investors
  786. SV Investment
  787. SV Life Sciences
  788. SVE Capital
  789. SwanBio Therapeutics
  790. Swiss Medica XXI Century
  791. Syncona
  792. SYZ Cell Therapy
  793. T. Rowe Price Associates
  794. Tactiva Therapeutics
  795. Taiwan Bio Therapeutics
  796. Takara Bio
  797. Takeda
  798. Takeda Pharmaceutical
  799. Takeda Pharmaceuticals
  800. Takeda Ventures
  801. Talaris Therapeutics
  802. Targazyme
  803. Target ALS Foundation
  804. Targovax
  805. Tasly Biopharmaceuticals
  806. Taysha Gene Therapies
  807. TC BioPharm
  808. TCG
  809. TCR CURE Biopharma Technology
  810. TCR2 Therapeutics
  811. T-Cure Bioscience
  812. Tech Coast Angels
  813. Techlife Capital
  814. Technium Partners
  815. Temasek
  816. Tenaya Therapeutics
  817. TeneoBio
  818. TeraImmune
  819. Terumo
  820. Tessa Therapeutics
  821. Tetragon Financial Group
  822. Tevogen Bio
  823. The Abby Grace Foundation
  824. The Baldota family
  825. The Baupost Group
  826. The Biotechnology Value Fund
  827. The Board of Trustees of the Leland Stanford Junior University
  828. The Column Group
  829. The Emmes Company
  830. The Pregene (ShenZhen) Biotechnology
  831. Théa Open Innovation
  832. TheraBiologics
  833. Theravectys
  834. Third Rock Ventures
  835. Tianhe Stem Cell Biotechnologies
  836. Tianjin Ever Union Biotechnology 
  837. Tianjin Mycure Medical Technology
  838. Tianjin Weikai Biological Engineering
  839. TICEBA
  840. TILT Biotherapeutics
  841. Timmune Biotech
  842. Tmunity Therapeutics
  843. Tolerion
  844. ToolGen
  845. TPG Biotech
  846. TRACT Therapeutics
  847. Transgene
  848. Transhuman Capital
  849. Triumvira Immunologics
  850. Trucode Gene Repair
  851. Trygve Schiørbeck
  852. Tscan Therapeutics
  853. Tsingyuan
  854. U.S. Stem Cell
  855. UCB Ventures
  856. UCL Technology Fund
  857. UF Innovate Ventures
  858. UK start-up investors UKI2S
  859. Ulmer Investment
  860. Ultragenyx
  861. uniQure Biopharma
  862. United Therapeutics
  863. University of California Berkeley
  864. Unum Therapeutics
  865. UPMC Enterprises
  866. Urovant Sciences
  867. UWELL Biopharma
  868. Valor Equity Partners
  869. V-Bio Ventures
  870. VBL Therapeutics
  871. VcanBio Center for Translational Biotechnology
  872. VCN Biosciences
  873. Venrock
  874. Vericel
  875. Verition Fund Management
  876. Versant Ventures
  877. Vertex Pharmaceuticals
  878. Verve Therapeutics
  879. ViaCyte
  880. Vida Ventures
  881. ViGenCell
  882. ViGeneron
  883. Viking Global Investors
  884. Vir Biotechnology
  885. ViroMed
  886. Viscofan BioEngineering
  887. Vivet Therapeutics
  888. Vivo Capital
  889. Voyager Therapeutics
  890. VREX Therapeutics
  891. VT BIO
  892. Waverly Capital
  893. Wellcome Trust
  894. Wellington Management Company
  895. Wellington Zhaotai Therapies
  896. Whitesun Healthcare Ventures
  897. WI Harper Group
  898. WindMIL Therapeutics
  899. Wize Pharma
  900. Woodford Investment Management
  901. Woodline Partners
  902. WRVI Capital
  903. Wugen
  904. Wuhan Bio-Raid Biotechnology
  905. Wuhan Sian Medical Technology
  906. WuXi AppTec and Sequoia Capital China
  907. Wyvern Pharmaceuticals
  908. Xi'An Yufan Biotechnology
  909. Xiangxue Life Sciences
  910. XyloCor Therapeutics
  911. Youkyung PSG Asset Management
  912. Ysios Capital
  913. YuanBio
  914. Yuanyi Biotechnology
  915. Zelluna Immunotherapy
  916. Zhujiang Hospital
  917. Ziopharm Oncology

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com